Production of Monoclonal Antibodies in E. coli
- Dorothea E. ReillyAffiliated withEarly Stage Cell Culture, Genentech, Inc.
- , Daniel G. YansuraAffiliated withAntibody Engineering, Genentech, Inc.
The number of monoclonal antibodies approved for use as therapeutic agents by regulatory agencies has increased in the past several years. Monoclonal antibodies are predicted to become an increasingly larger part of biopharmaceutical products, and perhaps dominate the market share by the end of the decade (Walsh 2006). Mammalian expression systems, such as Chinese Hamster Ovary cells (CHO), are currently the preferred system for producing full-length monoclonal antibodies. Fungal systems could become more of a contender for the production of antibodies if titers can be increased (Andersen and Reilly 2004). However, with fungal production systems, there may be concerns about potential non-native mammalian N-linked or O-linked glycosylation that could result in immunogenic responses in humans. Technology developed in recent years (Hamilton et al. 2003) could help to alleviate this concern.
- Production of Monoclonal Antibodies in E. coli
- Book Title
- Current Trends in Monoclonal Antibody Development and Manufacturing
- Book Part
- Part VII
- pp 295-308
- Print ISBN
- Online ISBN
- Series Title
- Biotechnology: Pharmaceutical Aspects
- Series Volume
- Springer New York
- Copyright Holder
- American Association of Pharmaceutical Scientists
- Additional Links
- Industry Sectors
- eBook Packages
- Editor Affiliations
- ID1. Genentech Inc.
- ID2. Omeros Corporation
- ID3. Boehringer Ingelheim Pharma KG
- ID4. Genentech, Inc.
- Author Affiliations
- 1. Early Stage Cell Culture, Genentech, Inc., South San Francisco, CA, USA
- 2. Antibody Engineering, Genentech, Inc., South San Francisco, CA, USA
To view the rest of this content please follow the download PDF link above.